FDA Drug Safety Initiative Is "Inadequate," JAMA Editorial Says
This article was originally published in The Pink Sheet Daily
Executive Summary
IoM study of drug safety system is "appropriate," but the "initial steps" proposed by FDA are not enough "to restore the trust and confidence necessary" for agency's public health mission. JAMA editors propose independent drug safety agency, with mandatory Phase IV studies.